(1r,4r)-6’-bromo-4-methoxy-1‘-methylene-1‘,3‘-dihydrospiro[cyclohexane-1,2‘-indene]

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: (1r,4r)-6’-bromo-4-methoxy-1‘-methylene-1‘,3‘-dihydrospiro[cyclohexane-1,2‘-indene]
• 英文别名: 5-bromo-4'-methoxy-3-methylidenespiro[1H-indene-2,1'-cyclohexane]
• 化学式: C₁₆H₁₉BrO
• 分子量: 307.23
• InChiKey: JVTLEXZGVCDOJD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (1r,4r)-6’-bromo-4-methoxy-1‘-methylene-1‘,3‘-dihydrospiro[cyclohexane-1,2‘-indene] 在 palladium 10% on activated carbon 、 氢气 、 碘 作用下， 以 甲醇 、 乙醚 为溶剂， 反应 75.0h， 生成 {(1r,4r)-4-methoxy-3‘H,5’‘H-dispiro[cyclohexane-1,2‘-indene1’,4”-oxazol]-2”-amine formate salt}
  参考文献：
  名称：

  [EN] COMPOUNDS AND THEIR USE AS BACE INHIBITORS
  [FR] COMPOSÉS ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE BACE

  摘要：

  本申请涉及式(I)、(Ia)或(Ib)的化合物及其药物组合物/制剂。本申请进一步涉及治疗或预防与Αβ相关的病理学，如唐氏综合症，β-淀粉样蛋白血管病，如但不限于脑淀粉样蛋白血管病或遗传性脑出血，与认知损害相关的疾病，如但不限于MCI（“轻度认知损害”），阿尔茨海默病，记忆丧失，与阿尔茨海默病相关的注意力缺陷症状，与疾病如阿尔茨海默病或痴呆症相关的神经退行性疾病，包括混合性血管性和退行性起源的痴呆，早老性痴呆，老年性痴呆和与帕金森病相关的痴呆的方法。

  公开号：

  WO2016055858A1
• 作为产物：
  描述：

  6'-bromo-4-hydroxyspiro[cyclohexane-1,2'-inden]-1'(3'H)-one 在 potassium tert-butylate 作用下， 以 四氢呋喃 、 正戊烷 为溶剂， 反应 11.25h， 生成 (1r,4r)-6’-bromo-4-methoxy-1‘-methylene-1‘,3‘-dihydrospiro[cyclohexane-1,2‘-indene]
  参考文献：
  名称：

  [EN] COMPOUNDS AND THEIR USE AS BACE INHIBITORS
  [FR] COMPOSÉS ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE BACE

  摘要：

  本申请涉及式(I)、(Ia)或(Ib)的化合物及其药物组合物/制剂。本申请进一步涉及治疗或预防与Αβ相关的病理学，如唐氏综合症，β-淀粉样蛋白血管病，如但不限于脑淀粉样蛋白血管病或遗传性脑出血，与认知损害相关的疾病，如但不限于MCI（“轻度认知损害”），阿尔茨海默病，记忆丧失，与阿尔茨海默病相关的注意力缺陷症状，与疾病如阿尔茨海默病或痴呆症相关的神经退行性疾病，包括混合性血管性和退行性起源的痴呆，早老性痴呆，老年性痴呆和与帕金森病相关的痴呆的方法。

  公开号：

  WO2016055858A1

文献信息

• [EN] INHIBITORS OF BETA-SECRETASE<br/>[FR] INHIBITEURS DE LA BÊTA-SECRÉTASE
  申请人：DILLARD LAWRENCE W

  公开号：WO2011106414A1

  公开（公告）日：2011-09-01

  The present invention relates to compounds represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. Definitions for the variables are provided herein.

  本发明涉及由结构式（I）表示的化合物或其药用盐。这里提供了变量的定义。
• INHIBITORS OF BETA-SECRETASE
  申请人：CACATIAN Salvacion

  公开号：US20110071126A1

  公开（公告）日：2011-03-24

  The present invention is directed to a compound represented by the following structural formula or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions and method of use of the compounds are also described.

  本发明涉及下述结构式所代表的化合物或其药学上可接受的盐。同时还描述了该化合物的药物组合物和使用方法。
• Inhibitors of beta-secretase
  申请人：Vitae Pharmaceuticals, Inc.

  公开号：EP2801570A1

  公开（公告）日：2014-11-12

  The present invention is directed to a compound represented by the following structural formula or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions and method of use of the compounds are also described.

  本发明涉及一种由以下结构式表示的化合物 或其药学上可接受的盐。本发明还描述了该化合物的药物组合物和使用方法。
• Compounds and their use as BACE inhibitors
  申请人：AstraZeneca AB

  公开号：US10053453B2

  公开（公告）日：2018-08-21

  The present application relates to compounds of formula (I), (Ia), or (Ib) and their pharmaceutical compositions/preparations. This application further relates to methods of treating or preventing Aβ-related pathologies such as Down's syndrome, β-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia, including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease.

  本申请涉及式(I)、(Ia)或(Ib)化合物及其药物组合物/制剂。本申请还涉及治疗或预防 Aβ 相关病症的方法，如唐氏综合征、β-淀粉样血管病变，如但不限于脑淀粉样血管病变或遗传性脑出血、与认知障碍相关的疾病，如但不限于 MCI（"轻度认知障碍"）、阿尔茨海默病、记忆力减退、与阿尔茨海默病相关的注意力缺陷症状、与阿尔茨海默病或痴呆等疾病相关的神经变性，包括血管性和变性混合性痴呆、老年前期痴呆、老年性痴呆和与帕金森病相关的痴呆。
• COMPOUNDS AND THEIR USE AS BACE INHIBITORS
  申请人：AstraZeneca AB

  公开号：US20170313686A1

  公开（公告）日：2017-11-02

  The present application relates to compounds of formula (I), (Ia), or (Ib) and their pharmaceutical compositions/preparations. This application further relates to methods of treating or preventing Aβ-related pathologies such as Down's syndrome, β-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI (“mild cognitive impairment”), Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia, including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease.